title: Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
abstract: OBJECTIVE
  To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS.
  
  
  METHODS
  This was a randomized clinical study. Eighteen women in groups A and B received medications for three cycles. Acne score, androgens and metabolic parameters were assessed before and after treatment.
  
  
  RESULTS
  One and two women in groups A and B, respectively, were excluded from the study. Both groups had significantly decreased acne score and free androgen index, and increased sex hormone-binding globulin levels. Cholesterol and high-density lipoprotein were significantly increased in group B, and androstenedione was significantly decreased in group A. The regular withdrawal bleeding was obtained in both groups.
  
  
  CONCLUSIONS
  Both regimens had quite similar efficacy on hyperandrogenism after three cycles of therapy and without any changes in metabolic parameters.
authors.affiliation: Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Supatra
authors.initials: S
authors.lastname: Leelaphiwat
authors.forename: Theerayut
authors.initials: T
authors.lastname: Jongwutiwes
authors.forename: Srithean
authors.initials: S
authors.lastname: Lertvikool
authors.forename: Chotika
authors.initials: C
authors.lastname: Tabcharoen
authors.forename: Matchuporn
authors.initials: M
authors.lastname: Sukprasert
authors.forename: Sasivimol
authors.initials: S
authors.lastname: Rattanasiri
authors.forename: Sawaek
authors.initials: S
authors.lastname: Weerakiet
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy / Q000209:etiology; D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000097:blood; D000735:Androstenedione / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D017135:Desogestrel / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy* / Q000209:etiology; D008075:Lipoproteins, HDL / Q000097:blood; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D003280:Contraceptives, Oral, Synthetic; D004967:Estrogens; D008075:Lipoproteins, HDL; D000451:Mineralocorticoid Receptor Antagonists; D012738:Sex Hormone-Binding Globulin; D013148:Spironolactone; D000735:Androstenedione; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D017135:Desogestrel; D002784:Cholesterol
keywords: combined oral contraceptive pills; cyproterone acetate; desogestrel; polycystic ovary syndrome; spironolactone